Aumentare il coinvolgimento dei pazienti nel processo decisionale della chirurgia del cancro al seno
Aumentare il coinvolgimento delle pazienti svantaggiate dal punto di vista socioeconomico nel processo decisionale per la chirurgia del cancro al seno attraverso un intervento decisionale condiviso
This trial studies how well a breast cancer surgery decision aid works in increasing patient engagement in decision making for patients with newly diagnosed stage 0-III breast cancer. The trial also examines barriers to patient engagement even with the use of a decision aid, and if barriers are more likely to be experienced by socioeconomically disadvantaged patients.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The primary and secondary objectives of the study:
PRIMARY OBJECTIVES:
I. Test the effectiveness of a breast cancer surgery decision aid in increasing patient engagement in decision making (measured by knowledge and power) in clinics serving a high proportion of socioeconomically disadvantaged patients.
II. Test the extent to which the effect of a decision aid on patient engagement is mediated through the mitigation of barriers and determine if persistent barriers are disproportionately experienced by socioeconomically disadvantaged patients.
SECONDARY OBJECTIVES:
I. Characterize how persistent barriers influence patient engagement in decision making in order to identify targets for adjunct interventions that could be implemented in clinics serving a high proportion of socioeconomically disadvantaged patients.
Trial Design:
OUTLINE: This is a multi-site cluster randomized trial using a stepped wedge design. Ten clinics will be recruited for participation. All clinics will begin in the usual care arm. Clinics will be randomized to the timing with which they cross-over to the decision aid intervention, with new clinics crossing over every 10 weeks.
ARM I: usual care
ARM II: decision aid intervention
The only difference between patients enrolled before institutional crossover and patients enrolled after institutional crossover is those who are enrolled after institutional crossover will have been offered the decision aid as accepted practice in the clinic.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Tamuning, Guam, 96913
- FHP Health Center-Guam
-
-
-
-
-
San Juan, Porto Rico, 00902
- Pan American Center for Oncology Trials LLC
-
-
-
-
California
-
Dublin, California, Stati Uniti, 94568
- Epic Care-Dublin
-
Emeryville, California, Stati Uniti, 94608
- Bay Area Breast Surgeons Inc
-
Emeryville, California, Stati Uniti, 94608
- Epic Care Partners in Cancer Care
-
Martinez, California, Stati Uniti, 94553-3156
- Contra Costa Regional Medical Center
-
Oakland, California, Stati Uniti, 94609
- Alta Bates Summit Medical Center - Summit Campus
-
Oakland, California, Stati Uniti, 94609
- Bay Area Tumor Institute
-
Walnut Creek, California, Stati Uniti, 94597
- Epic Care Cyberknife Center
-
-
Georgia
-
Augusta, Georgia, Stati Uniti, 30912
- Augusta University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Stati Uniti, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Stati Uniti, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Stati Uniti, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Stati Uniti, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, Stati Uniti, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Stati Uniti, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Stati Uniti, 96813
- Island Urology
-
Lihue, Hawaii, Stati Uniti, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Stati Uniti, 96701
- The Cancer Center of Hawaii-Pali Momi
-
‘Aiea, Hawaii, Stati Uniti, 96701
- Hawaii Cancer Care - Savio
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Stati Uniti, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Stati Uniti, 83617
- Walter Knox Memorial Hospital
-
Meridian, Idaho, Stati Uniti, 83642
- Idaho Urologic Institute-Meridian
-
Nampa, Idaho, Stati Uniti, 83686
- Saint Alphonsus Medical Center-Nampa
-
Post Falls, Idaho, Stati Uniti, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stati Uniti, 83864
- Kootenai Cancer Clinic
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- John H Stroger Jr Hospital of Cook County
-
Danville, Illinois, Stati Uniti, 61832
- Carle on Vermilion
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Urbana, Illinois, Stati Uniti, 61801
- The Carle Foundation Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70121
- Ochsner Medical Center Jefferson
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stati Uniti, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Deaconess Hospital
-
Great Falls, Montana, Stati Uniti, 59405
- Great Falls Clinic
-
Great Falls, Montana, Stati Uniti, 59405
- Benefis Healthcare- Sletten Cancer Institute
-
Helena, Montana, Stati Uniti, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Stati Uniti, 59901
- Kalispell Regional Medical Center
-
Missoula, Montana, Stati Uniti, 59804
- Community Medical Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87102
- University of New Mexico Cancer Center
-
-
Oregon
-
Baker City, Oregon, Stati Uniti, 97814
- Saint Alphonsus Medical Center-Baker City
-
Ontario, Oregon, Stati Uniti, 97914
- Saint Alphonsus Medical Center-Ontario
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Wisconsin
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
-
Wyoming
-
Cody, Wyoming, Stati Uniti, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Stati Uniti, 82801
- Welch Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Newly diagnosed with stage 0-III breast cancer
- Eligible patients must be planning breast surgery as a component of their definitive treatment
- Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
- Patients with hearing impairment requiring the use of an interpreter are not eligible for this study
- Patients must be able to speak English with the fluency required to have a direct discussion around treatment decision-making (i.e. without interpreter)
- CLINIC STAKEHOLDER (SURGEONS AND CLINIC STAFF): Breast surgeon(s) and nursing staff, medical assistant, or mid-level provider at each participating clinic who participates in the care of patients newly diagnosed with breast cancer
- INSTITUTIONAL: 10 clinics that annually provide surgical care for 120-300 patients newly diagnosed with breast cancer will be selected to participate in this study
- INSTITUTIONAL: Surgeons at eligible clinics must consent to the study as a requirement for site participation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm I (surgical consultation)
Prior to institutional crossover, participants receive care as per usual care. |
Usual Care |
|
Sperimentale: Arm II (web-based breast cancer surgery decision aid)
Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation.. |
Usual Care Web-based decision aid received prior to the surgical consultation |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient Power: Self-efficacy in Patient Physician Interactions
Lasso di tempo: 3 weeks
|
Power is defined as patients' self-perceived capacity to influence the decision-making encounter. This construct is measured using the Patient's Self-Efficacy in Patient-Physician Interactions (PEPPI)-5 point scale; the primary outcome measure is a total score ranging from 5-25, where higher scores indicate increased self-efficacy. The patient completes the PEPPI-5 questionnaire within 3 weeks post-surgical consultation. |
3 weeks
|
|
Patient Power: Active Patient Participation
Lasso di tempo: 1 day
|
Power is also separately measured by the validated Active Patient Participation Behaviors System to assess active patient participation during the surgeon consultation and is measured off the audio-recording of the consultation; a summary measure of patient's active involvement in the interaction is coded by the study team and represents a total count of patients' communicative behaviors (i.e., count of patient asking questions, count of patient assertive responses and count of patient expressions of concern) ranging from 0-114, where higher scores indicate increased active patient participation. The consultation for a patient will typically be study day 1 (day of registration). |
1 day
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient Knowledge
Lasso di tempo: Up to 3 weeks
|
Patient knowledge is measured from 5 knowledge questions in the Decision Quality Instrument-Breast Surgery survey, with a percent correct recorded as the secondary outcome measure, ranging from 0-100%. The patient completes the Decision Quality Instrument-Breast Surgery survey within 3 weeks post-surgical consultation. |
Up to 3 weeks
|
|
Percentage of Concordant Between Surgery Received and Patient Treatment Preference
Lasso di tempo: Up to 3 weeks
|
This binary outcome indicates whether the surgery received (mastectomy or lumpectomy) was concordant with the patient's treatment preference. Patient's goals/concerns (keep the breast, remove the breast for peace of mind, avoid radiation), rated from 0 (not at all important) to 10 (extremely important), and treatment preference (lumpectomy only, lumpectomy and radiation, mastectomy, other surgery, or not sure) are measured with the Decision Quality Instrument (DQI)-Breast Surgery survey, completed within 3 weeks post-consultation. Concordance is derived using the method of Sepucha et al. (2012): (1) estimate a predicted probability (pp) of surgery preference from a multivariable logistic regression model with patient's goals/concerns and stage as independent variables; (2) classify patients as concordant if pp >= 0.5 and mastectomy was received, or pp < 0.5 and lumpectomy was received; and (3) calculate the percentage of concordant. |
Up to 3 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Cattedra di studio: Heather B. Neuman,, MD, MS, University of Wisconsin, Madison
Pubblicazioni e link utili
Pubblicazioni generali
- Schumacher JR, Zahrieh D, Chow S, Taylor J, Wills R, Hanlon BM, Rathouz PJ, Tucholka JL, Neuman HB. Increasing socioeconomically disadvantaged patients' engagement in breast cancer surgery decision-making through a shared decision-making intervention (A231701CD): protocol for a cluster randomised clinical trial. BMJ Open. 2022 Nov 17;12(11):e063895. doi: 10.1136/bmjopen-2022-063895.
- Schumacher JR, Hanlon BM, Zahrieh D, Rathouz PJ, Tucholka JL, McKinney G, Tan AD, Breuer CR, Bailey L, Higham AM, Wecsler JS, Arnold AH, Froix AJ, Dull S, Abbott AM, Fine SG, McGuire KP, Seydel AS, McNamara P, Chow S, Neuman HB. Impact of a Web-Based Decision Aid on Socioeconomically Disadvantaged Patients' Engagement in Breast Surgery Decision-Making: Stepped-Wedge Clinical Trial (Alliance-A231701CD). Ann Surg Oncol. 2025 Aug;32(8):5540-5550. doi: 10.1245/s10434-025-17452-0. Epub 2025 May 17.
- Saucke MC, Jacobson N, McKinney G, Neuman HB. Role of the Surgeon in De-Escalating Emotion During a Breast Cancer Surgery Consultation: A Qualitative Study of Patients' Experiences in Alliance A231701CD. Ann Surg Oncol. 2024 Dec;31(13):8873-8881. doi: 10.1245/s10434-024-16156-1. Epub 2024 Sep 25.
- Zahrieh D, Croghan IT, Inselman JW, Mandrekar SJ. Guidelines for Data and Safety Monitoring in Pragmatic Randomized Clinical Trials Using Case Studies. Mayo Clin Proc. 2023 Nov;98(11):1712-1726. doi: 10.1016/j.mayocp.2023.02.019.
- Saucke MC, Jacobson N, Chow S, McKinney G, Neuman HB. Providing information to prepare breast cancer patients for their surgical consultation: barriers and recommendations (an analysis from Alliance A231701CD). Support Care Cancer. 2026 May 14;34(6):537. doi: 10.1007/s00520-026-10726-7.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- A231701CD
- NCI-2018-00643 (Identificatore di registro: NCI Clinical Trial Reporting Program)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Periodo di condivisione IPD
Beginning 6 to 12 months following article publication.
Criteri di accesso alla condivisione IPD
Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .